Kiora Pharmaceuticals (KPRX) EPS (Basic) (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has reported EPS (Basic) for 13 consecutive years, with -$0.34 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) rose 37.63% year-over-year to -$0.34; the trailing twelve-month figure through Jun 2026 stood at -$1.78 (up 40.79% YoY), and the FY2025 full-year result was -$2.6, down 380.15% from the prior year.
• EPS (Basic) improved to -$0.34 in Q2 2026 per KPRX's latest filing, from -$0.58 in the prior quarter.
• Across five years, EPS (Basic) topped out at $4.67 in Q1 2024 and bottomed at -$93.59 in Q3 2022.
• Historically, EPS (Basic) has averaged -$11.22 across 5 years, with a median of -$1.33 in 2024.
• The sharpest annual moves came in 2022 and 2024: EPS (Basic) tumbled 3417.14% in 2022, then soared 150.43% in 2024.
• Over 5 years, EPS (Basic) stood at -$63.13 in 2022, then surged by 87.22% to -$8.07 in 2023, then jumped by 86.49% to -$1.09 in 2024, then plunged by 43.4% to -$1.56 in 2025, then surged by 78.48% to -$0.34 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.34, -$0.58, and -$1.56 for Q2 2026, Q1 2026, and Q4 2025 respectively.